NYSE: DVA · Medical Care Facilities
DaVita (DVA) fair value: undervalued or overvalued?
As of 14 Nov 2026, Faircurve's model values DaVita (DVA) at $212.79 a share. The stock last closed at $173.00, which puts the model's fair value 23.0% above the price. On the model's bands that reads as Undervalued.
Revalued . Price is the close of 17 Nov 2026. DaVita Inc.
The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.
This week, in three parts
What happenedThe run of 14 Nov 2026 moved the fair value from $210.28 to $212.79 (+1.2%). The peer group changed: most of the move.
What the model makes of itThe price of $173.00 is 23.0% below it: Undervalued, on a medium evidence grade.
What's nextNext report on 1 Feb 2027. Options prices imply a move of about 11% either way over the next month. On the model's Scorecard Leaders list since 10 Nov 2026 (a strategy with a proving record). The next weekly run is on Saturday 21 Nov 2026.
What price range does the model give DVA?
The calibrated range for DVA over 63 trading days is $153.00 to $196.83. It sits around the last close, and its width comes from the volatility that DVA's own options imply (37% a year), calibrated weekly against realised prices (n = 8,038 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $133.43 to $308.85. In 64% of the simulations the fair value came out above the price the model ran on.
Faircurve Insights · 14 Nov 2026
DaVita Inc. (DVA) provides kidney dialysis treatments and comprehensive renal care to people with chronic kidney failure. It operates in healthcare, within medical care facilities.
Faircurve's model put the fair value at $212.79 a share on 14 Nov 2026, the midpoint of 2,000 simulations. The previous run, on 7 Nov 2026, gave $210.28, so the fair value moved +1.2%. In the model's own words, the peer group changed: most of the move. The calibrated range over 63 trading days is $152.02 to $201.04. Ranges built this way held the price 60% of the time at this horizon, based on 8,038 past valuations refreshed on 14 Nov 2026. The evidence grade is Medium. It reflects how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say whether the fair value is right.
The model's overall quality score is 71 out of 100, a composite of six factors scored against comparable companies. Three stand out. Capital discipline scores 89, with net buybacks at 14.8% of market value against a peer median of 1.5%. Earnings quality scores 85, with free cash flow to net income at 1.41x against a peer median of 1.38x. The balance sheet scores 23, with net debt to EBITDA at 4.61x against a peer median of 3.14x. The model compares it with ten comparable companies.
Written from the figures on this page for the 14 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
The Global Pulse
Faircurve's note after each US session, in your inbox. No account needed.
When does DVA report earnings, and how has the stock reacted?
DaVita's next earnings report is scheduled for 1 Feb 2027. Companies can move their dates.
Options prices on 17 Nov 2026 imply a move of about 8.5% in either direction through the nearest expiry, about 30 days out. That is the size the market is pricing, not a direction. DVA's 30 day implied volatility works out to about 10.7% over one month.
On 12 Nov 2026 DVA moved 5.1% in one session, against the 2.2% a day that options had priced: 2.3 times the implied size.
Around its last 8 reports: what the options market priced, and what followed
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across DVA's last 8 reports, ignoring direction, was 8.4%.
What the options market has priced for a month's move in DVA
How does DVA score on business quality?
DaVita's overall quality score is 71 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.
| Factor | Score (0 to 100) | Headline measure | Peer median |
|---|---|---|---|
| ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend. | 79 | 11.8%ROIC | 7.0% |
| Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash). | 85 | 1.41xFCF / net income | 1.38x |
| Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes. | 51 | 6.5%Revenue growth, trailing | 6.5% |
| Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks. | 89 | 14.8%Net buybacks / market value | 1.5% |
| Balance sheetNet debt to EBITDA and interest coverage. | 23 | 4.61xNet debt / EBITDA | 3.14x |
| StabilityDownside volatility of the EBITDA margin over the last five years. | 84 | 1.0 ptsEBITDA margin downside volatility, 5y | 2.5 pts |
How does DVA compare with similar companies?
The companies in medical care facilities closest to DaVita in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| ENSG The Ensign Group, Inc. | $186.02 | $174.98 | -5.9% | Fairly valued |
| UHS Universal Health Services, Inc. | $191.98 | $310.03 | +61.5% | Gap wider than 60% |
| EHC Encompass Health Corporation | $137.88 | $139.30 | +1.0% | Fairly valued |
| CHE Chemed Corporation | $546.75 | $568.98 | +4.1% | Fairly valued |
| CON Concentra Group Holdings Parent, Inc. | $42.38 | $43.92 | +3.6% | Fairly valued |
| THC Tenet Healthcare Corporation | $282.07 | $371.67 | +31.8% | Undervalued |
| OPCH Option Care Health, Inc. | $31.63 | $32.92 | +4.1% | Fairly valued |
| HIMS Hims & Hers Health, Inc. | $17.55 | $21.46 | +22.3% | Undervalued |
What the comparable companies' multiples alone would give for DVA, the peer-implied price, is $382.82 a share on this run. The fair value weighs that against the company's own multiple.
All medical care facilities stocks ranked by gap to fair value
DaVita at a glance
DaVita Inc. specializes in delivering essential kidney dialysis treatments and comprehensive renal care to individuals grappling with chronic kidney failure.
- Market value
- $11.0B
- Sector
- Healthcare
- Industry
- Medical Care Facilities
- Revenue expected, next twelve months
- $14.6B
- Consensus revenue growth, next fiscal year
- +4.0%
- Analysts with estimates
- 4
- Beta to the US market
- -0.24
- First valued by Faircurve
- 1 May 2026
At the close of 17 Nov 2026, 62.4% of the 1,083 graded US stocks the model covers traded below the model's fair value. DVA was among them.
How the fair value is worked out: the model prices DaVita on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 7 Nov 2026 the model's fair value for DVA was $210.28. As of 14 Nov 2026 it is $212.79, a change of +1.2%. The peer group changed: most of the move. The model revalues every stock it covers each week, and again after an earnings report.
Questions about DaVita's valuation
Is DaVita stock undervalued or overvalued?
On Faircurve's model, DVA reads as Undervalued as of 14 Nov 2026. The model's fair value is $212.79 a share against a last close of $173.00, a gap of +23.0%.
What is DVA's fair value?
$212.79 a share as of 14 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $133.43 to $308.85.
What price range does the model give DVA?
$153.00 to $196.83 over 63 trading days. Ranges built this way held the price 60% of the time across 8,038 past valuations, refreshed 14 Nov 2026.
When does DaVita report earnings next?
The next report is scheduled for 1 Feb 2027. Companies can move their dates.
How much has DVA moved on past earnings reports?
Across its last 8 reports the median two session move was 8.4%, ignoring direction. The largest was +25.8% around the report of 5 May 2026.
How confident is the model in this valuation?
The model's evidence grade for DVA is medium. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.
The model's own ideas on DVA
The model has an idea open on DVA under Scorecard Leaders since 10 Nov 2026, a strategy with a proving record. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on DVA with their outcomes. A free account is enough.